Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer

Immune checkpoint inhibition combined with chemotherapy is currently approved as first-line treatment for patients with advanced PD-L1–positive triple-negative breast cancer (TNBC). However, a significant proportion of metastatic TNBC is PD-L1–negative and, in this population, chemotherapy alone lar...

Descripción completa

Detalles Bibliográficos
Autores principales: Alečković, Maša, Li, Zheqi, Zhou, Ningxuan, Qiu, Xintao, Lulseged, Bethlehem, Foidart, Pierre, Huang, Xiao-Yun, Garza, Kodie, Shu, Shaokun, Kesten, Nikolas, Li, Rong, Lim, Klothilda, Garrido-Castro, Ana C., Guerriero, Jennifer L., Qi, Jun, Long, Henry W., Polyak, Kornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618734/
https://www.ncbi.nlm.nih.gov/pubmed/37676980
http://dx.doi.org/10.1158/1535-7163.MCT-23-0303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618734/
https://www.ncbi.nlm.nih.gov/pubmed/37676980
http://dx.doi.org/10.1158/1535-7163.MCT-23-0303

Ejemplares similares